openPR Logo
Press release

Approval for commercialization of Heberprot-P® in Mexico

05-04-2018 05:09 PM CET | Health & Medicine

Press release from: Center for Genetic Engineering and Biotechnology

Approval for commercialization of Heberprot-P® in Mexico

Havana, Cuba, May 4, 2018 – Heberprot-P® has been approved for commercialization in México. The Center for Genetic Engineering and Biotechnology (CIGB) is excited to announce regulatory approval of this innovative medicine indicated for advanced diabetic foot ulcer (DFU), which is expected to save thousands of people from lower limb amputation. The official approval date of Heberprot-P® was April 30th, 2018. Heberprot-P® stimulates granulation, accelerates DFU re-epithelization, and reduces healing time, surgical debridement, amputation risk, and recurrences. The intralesional infiltration of Heberprot-P® may be applied in combination with Good Wound Care (GWC), revascularization, and antibiotics. This medicine is an effective solution for an unmet medical need, a first in class product, unique worldwide, for DFU treatment. It is the only therapeutic choice available for advanced and complex DFU, reluctant to healing (grades 3, 4, and 5, according to Wagner’s classification).

Clinical experience derived from the intervention with Heberprot-P® in daily medical practice in Cuba was analyzed in 2013 in a study that reviewed the evolution of more than 2 000 patients as well as the pharmacovigilance of 1 788 patients, showing a 75% probability of granulation response, 61% healing rate, 71% amputation risk reduction, Bayes' favorable factor (5.40), and complete granulation in 76% of ulcers in 5 weeks (Adv. Pharmacoepidem. 2013, 2 (2): 1000128; BMC Pharm. & Toxicol, 2013, 14: 44). The International Working Group of Diabetic Foot (IWGDF) evaluated results of the clinical trial performed with Heberprot-P® in Cuba and reported in 2009 as promising, highlighting the results obtained in only 2 weeks of treatment (Diabetes Metab Res Rev 2012; 28 (Suppl 1): 119-141).

In a later systematic review, clinical trials comparing the use of growth factors with GWC (Cochrane Database of Systematic Reviews 2015, Issue 10, Art. No. CD008548), the IWGDF’s evaluation was reported on all major issues and requirements of Heberprot-P® clinical trials in Cuba. Similar criteria were expressed by the IWGDF in the guidelines on DFU healing (IWGDF Guidance, 2015: 10). A fourth study reported similar observations on the intralesional EGF infiltration method: "... a highly significant difference between groups in the prevalence of granulation tissue after just 2 weeks" (Diabetes Metab Res Rev 2016; 32 (Suppl 1): 154- 168).

Results of clinical studies performed in Cuba, Russia, Turkey, Vietnam, Argentina, Mexico, and Ukraine were enough to demonstrate safety and efficacy profile of Heberprot-P®. This medicine has been used in more than 290 000 patients with diabetic foot ulcer (DFU) in Russia, Belarus, Georgia, Ukraine, Turkey, Algeria, China, Panama, Argentina, Cuba, Dominican Republic, Venezuela, Ecuador, Libya, Uruguay, Paraguay, Colombia, Guatemala, Philippines, Vietnam, Nicaragua, Saudi Arabia, Indonesia, Seychelles, Saint Lucia, Saint Vicente, Sri Lanka, Jordan, and Kuwait.

A national survey of health and nutrition in Mexico reported that prevalence of diabetes is 9.4% of total population, which sums up more than 11 million people, 9.1% of adult diabetic suffers DFU, and amputation is indicated to 5.5% of adult diabetics (National Survey of Health and Nutrition, INEGI 2016). According to recent reports, lower limb amputation is the unique alternative for 45% of diabetics with advanced DFU in Mexico (Diabet. Foot. Ankle. 2017 Sep 6, 8 (1): 1367210). In a previous study, similar results were reported: 42% patients with advanced DFU required major amputation (Wound Repair & Regen. 24 (5): 923-927).
Written by Jose A. Buxado, MSc., Assistant Researcher, CIGB.

The Center for Genetic Engineering and Biotechnology of Havana is an institution devoted to research, development, manufacturing, and commercialization of products and technology derived from life science.

Alyane Vazquez González, BA., Communication & Media, e-mail: alyane.vazquez@cigb.edu.cu. Ave 31 e/ 158 y 190, Playa, P.O. Box 6162, Habana 10600, Cuba.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Approval for commercialization of Heberprot-P® in Mexico here

News-ID: 1040333 • Views: 893

More Releases from Center for Genetic Engineering and Biotechnology

Researchers defeat cancer once again
Havana, September 17, 2018. The Center for Genetic Engineering and Biotechnology (CIGB) is pleased to announce positive outcomes of an innovative medicine developed by CIGB's researchers intended to inhibit growth of tumor cell lines representative of basal-cell carcinoma of the skin, and malignant gliomas. This new medicine, designed as a synergic combination of recombinant human interferons alpha 2b and gamma, has been approved for commercialization in Cuba, and registered with
CIGB’s researchers defeat cancer once again
Havana – September 13, 2018. The Center for Genetic Engineering and Biotechnology (CIGB) is pleased to announce favorable results of an innovative medicine developed by Cuban researchers and engineers intended to inhibit growth of tumor cell lines representative of basal-cell carcinoma of the skin, and malignant gliomas. This new medicine, designed as a synergic combination of recombinant human interferons alpha 2b and gamma, has been approved for commercialization in Cuba,
President of India visits CIGB today to reinforce bilateral trade and scientific …
Havana, June 22nd, 2018 - The 14th and current President of India, in office since July 25th 2017, Ram Nath Kovind (b. 1945) visited the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba. President Ram Nath Kovind was received by the President of BioCubaFarma, Dr. Eduardo Martínez, and the General Director of the CIGB Dr. Eulogio Pimentel. This is a very important date in the agenda of Mr.

All 4 Releases


More Releases for DFU

Diabetic Foot Ulcer (DFU) Therapy Market Size, Key Company Profiles, Types, Appl …
Credible Markets has added a new key research reports covering Diabetic Foot Ulcer (DFU) Therapy market. The study aims to provide global investors with a game-changing decision making tool covering key fundamentals of the Diabetic Foot Ulcer (DFU) Therapy market. The research report will include total global revenues in the market with historical analysis, key figures including total revenues, total sales, key products, instrumental drivers, and challenges. The report data
Diabetic Foot Ulcer (DFU) Market Report 2021 by Supply, Demand, Consumption, Sal …
Diabetic Foot Ulcer (DFU) Market Diabetic Foot Ulcer (DFU) Pipeline Analysis” gives comprehensive insights on the various drugs being developed for the treatment of DFU. The report covers all the drugs that are in various phases of development (Discovery, Preclinical and Clinical). The pipeline focuses on novel pharmacologic drugs and regenerative medicines covering, antibodies, stem cell therapies, recombinant proteins, Peptide therapies, RNA-based therapeutics and others, but excludes symptom relief drugs, wound dressing,
Global Diabetic Foot Ulcer (DFU) Treatment Market to Witness an Impressive Growt …
The comprehensive research report titled “Global Diabetic Foot Ulcer (DFU) Treatment Market to Witness an Impressive Growth during the Forecast Period 2020 to 2026” by Zion Market Research supports the reader by assisting to accumulate all possible strategies based on valuable insights in order to maintain the correct tempo with the changing dynamics of the market in the present as well as few years down the line. Global Diabetic Foot Ulcer
Global Diabetic Foot Ulcer (DFU) Treatment Market To Record Exponential Growth D …
"The Zion Market Research added a new report “Diabetic Foot Ulcer (DFU) Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026” in its database, which provides an expert and in-depth analysis of key business trends and future market development prospects, key drivers and restraints, profiles of major market players, segmentation and forecasting. The global Diabetic Foot Ulcer (DFU) Treatment Market report offers a complete overview of the Diabetic
Diabetic Foot Ulcer (DFU) Treatment Market, Share, Development forecast to 2024
New report published by Global Info Research which offers insights on the Global Diabetic Foot Ulcer (DFU) Treatment market. Diabetic foot ulcer is a major complication of diabetes mellitus, and probably the major component of the diabetic foot. Click to view the full report TOC, figure and tables: https://www.globalinforesearch.com/global-diabetic-foot-ulcer-dfu-treatment-market_p102351.html Global Diabetic Foot Ulcer (DFU) Treatment Market: Forecast by Type / Application / Region The global Diabetic Foot Ulcer (DFU) Treatment market is valued at xx million USD in 2018
Diabetic Foot Ulcer (DFU) Therapeutics Industry Analysis, Size, Distribution Sha …
"The Latest Research Report Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Diabetic Foot Ulcer (DFU) Therapeutics Market GlobalData, the industry analysis specialist, has released its new report, Diabetic Foot Ulcer (DFU) Therapeutics Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and